2019 International Congress Archives - Page 203 of 217

Early diagnosis of progressive supranuclear palsy using quantitative MRI analysis of brain structure

K. Seo, T. Yamamoto, H. Kawasaki, T. Hukuoka, Y. Nakazato, K. Takahashi, I. Matunari, H. Matuda, N. Tamura, N. Araki (Saitama, Japan)
Early Impairment of Chopsticks Skill Predict Atypical Parkinsonism

YE. Kim, H. Ma, YJ. Kim (Anyang-Si, Republic of Korea)
Early onset parkinsonism and optic atrophy due to SLC25A46 mutations

G. Bitetto, MC. Malaguti, E. Monfrini, A. Di Fonzo (Milan, Italy)
Early postural instability is an effective predictor of future freezing of gait in Parkinson’s disease

J. Lee (Goyang-Si, Republic of Korea)
Early stage Parkinson’s disease patients with GBA mutation have more severe motor symptoms and difficult to differentiate in routine clinical practice

S. Abe, K. Komatsu, H. Satoi, H. Saiki, Y. Oka (Osaka, Japan)
eCARE-PD, a digital health platform for patient empowerment and online health tracking: experiences with co-design

T. Mestre, S. Grosjean, L. Bonneville, D. Grimes, E. Bate, M. Lê (Ottawa, ON, Canada)
Ecopipam, a selective D1 antagonist in development for the treatment of Tourette syndrome in children and adolescents: The Phase 2b D1AMOND Study

J. Dubow, D. Kim, R. Bittman, S. Wanaski, J. Swalec, T. Cunniff (Northbrook, IL, USA)
EEG guided neurofeedback boosts effects of motor cortex neuromodulation of rTMS in Parkinson´s Disease Patients

J. Romero, A. Arroyo, J. Andreo, M. Del Castillo, J. Serrano, E. Rocon, N. Malpica, E. Melero, E. Sanz, M. Gil, E. Rodriguez (Madrid, Spain)
Effect of 8-Weeks Treadmill Training on Selected Gait Parameters and Quality of Life of Patients with Parkinson’s Disease

A. Ogundele, M. Olaogun, M. Komolafe (Ile Ife, Nigeria)
Effect of a Combined Treatment with Botulinum Toxin and Biofeedback Exercises in Pisa Syndrome

A. Castagna, A. Crippa, D. Anastasi, M. Meloni, A. Montesano, A. Marzegan (Milano, Italy)
Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)

N. Hattori, T. Nomura, P. Salzman, H. Kitabayashi, M. Ishiuchi, K. Toyama, A. Mori (Tokyo, Japan)
Effect of Balanced Based Torso Weighting on gait in parkinsonism

D. Safarpour, M. Mancini, C. Murchison, S. Wood, A. Lesher, J. Duda, J. Morley (Philadelphia, PA, USA)
Effect of Botulinum Toxin Treatment on Cervical Dystonia

S. Tomic, M. Tomasevic, D. Hardi, T. Gilman Kuric, Z. Popovic (Osijek, Croatia)
Effect of Deep brain stimulation and Continuous infusion of levodopa-carbidopa intestinal therapy on non-motor symptoms in patients with advance Parkinson’s disease

V. Vuletic (Rijeka, Croatia)
Effect of deep brain stimulation on endothelial function and heart rate variability in Parkinson’s disease

JH. Yoon, DG. Park (Suwon, Republic of Korea)
Effect of dopamine D2-receptor antagonist and basal ganglia neuromodulation on neuronal activity in the cerebral motor area and cerebellar dentate nucleus

K. Schwabe, A. Abdulbaki, S. Helgers, J. Krauss, M. Alam (Hannover, Germany)
Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease

N. Miyaue, M. Nomoto, H. Yabe, Y. Yamanishi, S. Tada, R. Ando, M. Kubo, M. Nagai (Ehime, Japan)
Effect of global cognitive score on motor and quality of life outcomes after deep brain stimulation in patients with Parkinson’s disease or essential tremor

E. Staikova, D. Loring, M. Delong, S. Triche, C. Buetefisch, C. Esper, T. Wichmann, L. Scorr, L. Higginbotham, P. Aia, S. Factor, S. Miocinovic (Atlanta, GA, USA)
Effect of Levodopa on gut microbiome in Parkinson’s Disease (PD)

A. Hannoun, D. Ward, J. Flahive, J. Friedman, A. Deb, K. Smith (Worcester, MA, USA)
Effect of Medication Review on Reported Symptoms in Parkinson’s disease Patients

C. Stuijt, T. Laar (Groningen, Netherlands)
Effect of neurofeedback facilitation of the gait and balance imagery-related SMA activation on gait function in PD

M. Mihiara, H. Otomune, Y. Kajiyama, H. Fujimoto, N. Hattori, I. Miyai, K. Hanayama, Y. Sunada, H. Mochizuki (Kurashiki, Japan)
Effect of non-contact boxing on non-motor symptoms in Parkinson’s disease

A. Ghaffar, R. Gallagher, L. Rubin, S. Dharia, L. Ketigian, J. Whalen, Z. Scheid, K. Patel, J. Zhu, C. Michaelides, A. Leder (Old Westbury, NY, USA)
Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide

G. Loewen, G. Liang, R. Jimenez, K. Olson, E. Smith, H. Bozigian (San Diego, CA, USA)
Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience

J. Rocha, E. Tolosa, J. Ferreira, A. Lees, O. Rascol, W. Poewe, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)
Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study

I. Straka, M. Minár, M. škorvánek, M. Grofik, J. Benetin, P. Valkovič (Bratislava, Slovakia)
Effect of polygenic load on striatal dopaminergic deterioration in Parkinson’s disease

KJ. Pak, MJ. Lee (Busan, Republic of Korea)
Effect of Rehabilitation on Freezing of Gait in Parkinson’s disease: A meta-analysis

M. Gilat, P. Ginis, N. D'Cruz, A. Nieuwboer (Leuven, Belgium)
Effect of rTMS over supplementary motor area on motor cortical excitability: a study using realistic sham stimulation as placebo

S. Kodama, M. Hamada, Y. Shirota, T. Sasaki, K. Sato, J. Otsuka, C. Hosoda, Y. Ugawa, T. Toda (Tokyo, Japan)
Effect of Speech therapy in the sleep of patients with Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3)

G. Diaféria, JL. Pedroso, S. Park, F. Haddad, L. Haddad, L. Prado, G. Prado, O. Barsottini (São Paulo, Brazil)
Effect of Subthalamic Deep Brain Stimulation (DBS) on Impulsive Control Disorders (ICD) and Dopamine Dysregulation Syndrome (DDS) – A Randomized Controlled Trial Evaluating Deep Brain Stimulation Using a New Multiple Source, Constant-Current Rechargeable System for Management of Symptoms of Parkinson’s Disease (INTREPID)

M. Okun, R. Jain, L. Chen, I. Study Group, A. Tröster (Gainesville, FL, USA)
Effective deep brain stimulation co-modulate cross-frequency coupling

S. Groppa, M. Glaser, N. Koirala, M. Bange, M. Muthuraman (Mainz, Germany)
Effectiveness and safety of a herbal medication, HH368, for clinical symptoms of idiopathic Parkinson’s disease: a randomized controlled, pilot trial protocol

KH. Cho, SW. Kwon, C. Jin, WS. Jung, SK. Moon, SH. Lee (Seoul, Republic of Korea)
Effectiveness of exome sequencing in Parkinson’s disease of Chinese population

YW. Zhao, HX. Pan, L. Jiang, Y. He, Q. Zeng, XT. Zhou, XX. Zhou, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)
Effectiveness on the balance and the walking of a program of home-rehabilitation by digital support versus paper book on Parkinson’s patients: a randomized controlled trial.

M. Moreau, B. Fraudet, P. Gallien, B. Nicolas, E. Leblong (Rennes, France)
Effects of an intensive rehabilitation program (SIROCCO) on prefrontal activity during walking in patients with Parkinson Disease

I. Hoang, M. Ranchet, M. Cheminon, R. Derollepot, H. Devos, S. Perrey, J. Luauté, L. Paire-Ficout, T. Danaila (Bron, France)
Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease

P. Carlson-Kuhta, N. Hasegawa, SH. Jung, V. Shah, A. Ragothaman, D. Peterson, K. Smulders, L. King, M. Mancini, J. Lapidus, J. Nutt, F. Horak (Portland, OR, USA)
Effects of dance and walking program on spatiotemporal gait parameters in Parkinson’s disease

A. Nogueira Haas, M. Santos Delabary, R. Gimenes Donida, M. Wolffenbuttel, E. Passos Monteiro, L. Peyré-Tartaruga (Porto Alegre, Brazil)
Effects of deep brain stimulation of the subthalamic nucleus on the postoperative levodopa response: one year follow up

E. Kocabicak, O. Yildiz, D. Aygun, Y. Temel (Maastricht, Netherlands)
Effects of Directional Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson’s disease

G. Tommasi, L. Bertolasi, A. Nicolato, F. Sala, B. Bonetti, M. Longhi (Verona, Italy)
Effects of exergaming on attentional deficits and dual-tasking in Parkinson’s disease

E. Schaeffer, J. Busch, B. Roeben, S. Otterbein, P. Saraykin, E. Leks, I. Liepelt-Scarfone, M. Synofzik, M. Elshehabi, W. Maetzler, C. Hansen, S. Andris, D. Berg (66041, Germany)
Effects of gender on caregiving in Parkinson’s disease

S. Horn, S. Wu, Y. Dai, F. Cubillos, N. Dahodwala (Miami, FL, USA)
Effects of Handwriting Exercise on Functional Outcome in Parkinson’s Disease: A Randomized Controlled Trial

N. Vorasoot, P. Termsarasab, K. Thadanipon, T. Pulkes (Bangkok, Thailand)
Effects of levodopa on LTP-like plasticity induced by quadripulse magnetic stimulation in Parkinson’s disease

S. Moriyasu, T. Shimizu, T. Honda, Y. Ugawa, R. Hanajima (Yonago, Japan)
Effects of levodopa on prosaccade performance and visual target eccentricity

A. Yugeta, Y. Terao, Y. Ugawa (Tokyo, Japan)
Effects of multi-professional education program for management of Parkinson’s disease alterations on quality of life of people who are living with disease: a randomized clinical trial

C. Dias, A. Costa, E. Okamoto, A. Sartori, C. Silva, M. Piemonte (São Paulo, Brazil)
Effects of rechargeable battery of deep brain stimulation on the quality of life and satisfaction in patients with Parkinson’s disease

S. Jo, KW. Park, N. Choi, MS. Kim, HS. Ryu, SJ. Chung (Seoul, Republic of Korea)
Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats

CA. Pisanò, A. Brugnoli, S. Novello, C. Caccia, C. Keywood, E. Melloni, G. Padoani, S. Vailati, M. Morari (Ferrara, Italy)
Effects of the Neuromodulation of Sensorimotor Rhythms on the Event-Related Desynchronization Phenomenon in Parkinson’s Disease

MD. Del Castillo, JI. Serrano, E. Rodríguez, E. Rocon, JP. Romero, J. Andreo, A. Arroyo, N. Malpica, H. Melero, M. Gil, E. Sanz (Madrid, Spain)
Effects of three different physical therapies in body composition of Parkinson’s disease

AOF. Fagundes, EPM. Monteiro, MSD. Delabary, APZ. Zanardi, MZC. Casal, VFM. Martins, MW. Wolffenbuttel, ANH. Haas, FGM. Martinez, LPT. Tartaruga (Porto Alegre, Brazil)
Effects of Virtual Reality Exercise Program using the Sony PlayStation 2 gaming platform on Balance, Emotion and Quality of Life in Patients with Parkinson’s Disease

G-H. Lee (Cheonan, Republic of Korea)
Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials

K. Hasegawa, J. Goldman, T. Odawara, K. Kochi, O. Konishi, H. Maruyama, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Kanagawa, Japan)
Efficacy and Safety of AbobotulinumtoxinA in Adults with Cervical Dystonia: Similar Results Between 1mL and 2mL Dilution Methods

K. Dashtipour, R. Hauser, S. Isaacson, D. Truong, L. Bahroo, A. Patel, P. Maisonobe, J. Otto (Loma Linda, CA, USA)
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson’s disease.

M. Meloni, M. Puligheddu, M. Carta, M. Figorilli, G. Defazio (Cagliari, Italy)
Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.

M. Meloni, M. Puligheddu, A. Cannas, M. Figorilli, G. Defazio, M. Carta (Cagliari, Italy)
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson’s Disease.

M. Meloni, M. Figorilli, M. Carta, L. Tamburrino, A. Cannas, M. Fantini, G. Defazio, M. Puligheddu (Cagliari, Italy)
Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials

J. Goldman, K. Hasegawa, T. Odawara, K. Kochi, H. Maruyama, O. Konishi, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Chicago, IL, USA)
Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study

S. Isaacson, R. Pahwa, S. Thakkar, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Boca Raton, FL, USA)
Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)

P. Lewitt, N. Hattori, A. Mori, K. Toyama, E. Ohta, P. Salzman, S. Isaacson (West Bloomfield, MI, USA)
Efficacy of Motor Imagery Questionnaire-RS as a Diagnostic Tool in Rehabilitation of Movement Disorders

D. Kaur, N. Bhardwaj, S. Kumari, S. Kumari, A. Gupta, G. Kumar (Patna, India)
Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.

A. Lees, J. Ferreira, O. Rascol, W. Poewe, F. Stocchi, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)
Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, A. Antonini, H. Reichmann, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)
Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, O. Rascol, W. Poewe, E. Tolosa, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)
Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience

J. Rocha, F. Stocchi, A. Lees, J. Ferreira, W. Poewe, O. Rascol, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)
Efficacy of Stereotactic lesioning in Multi-etiological tremor

D. Srinivas, R. Yadav, P. Pal (Bangalore, India)
Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease

D. Gray, R. Riesenberg, J. Werth, Y. Zhang, M. Versavel, S. Duvvuri (Boston, MA, USA)
Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease

C. Olanow, F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, R. Kleiman, D. Blum, B. Navia (New York, NY, USA)
Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)
Embouchure dystonia evoked with tactile stimulation recorded by MEG

B. Bulica, C. Sidiropoulos, A. Mahajan, A. Zillgitt, S. Bowyer (Royal Oak, MI, USA)
Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration

J. Cedarbaum, K. Taylor, D. Hill, R. Alexander, Y. Luo, R. Rubens, N. Zach, J. Cosman, A. Dowling, K. Fisher, L. Oliva, J. Hitchcock, M. Lawton, D. Conrado, K. Romero, M. Minchik, D. Meulien, B. Yang, M. Forman, L. Bataille, D. Dexter, J. Gallagher, M. Braxenthaler, M. Lindemann, B. Boroojerdi, G. Stebbins, B. Bloem, M. Hu, E. Dorsey, D. Stephenson (Cambridge, MA, USA)
Encephalomyelopathy Due to Cerebrotendinous Xanthomatosis

ACO. Oliveira, LFV. Vasconcellos, BXC. Cordeiro, LLN. Najar (Rio de Janeiro, Brazil)
Enhancing the Proteasomal Degradation of Alpha Synuclein: “The Hallmark” to attenuating the Progression of Parkinson’s Disease

B. Adebisi, M. Adeleke (Osogbo, Nigeria)
Entity of excessive daytime sleepiness in Parkinson’s disease

O. Iakovleva, O. Levin, M. Poluektov (Moscow, Russian Federation)
Environmental toxicants and Parkinson’s disease in south of Morocco

Y. Naji, N. Kissani (Marrakech, Morocco)
Epidemiological study of multiple system atrophy: data from HoRC-MSA Project 2014-2019

M. Matsushima, I. Yabe, K. Sakushima, I. Iwata, Y. Kanatani, N. Nishimoto, T. Matsuoka, T. Katayama, H. Uesugi, K. Sako, A. Takei, A. Tamakoshi, S. Shimohama, N. Sato, S. Kikuchi, H. Sasaki (Sapporo, Japan)
Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)
Estimating the long-term effect of early levodopa treatment initiation in Parkinson’s disease

L. Vd Heuvel, J. Krijthe, L. Evers, M. Meinders, B. Post, T. Heskes, B. Bloem (Nijmegen, Netherlands)
Etiology and Clinical Study of Basal Ganglionic Lesions in a Sample of Egyptian Children

H. Zehry, S. Darwish, H. Gad, S. El Zayat, M. Tharwat, H. Emam (Dakahlyia, Egypt)
Evaluating IL6 and mitochondrial DNA levels as a potential biomarker in carriers of Parkin and PINK1 mutations

M. Borsche, I. König, S. Delcambre, S. Petrucci, A. Balck, T. Gasser, N. Brüggemann, S. Pereira, K. Badanjak, K. Brockmann, E M. Valente, R. Youle, A. Grünewald, C. Klein (Lübeck, Germany)
Evaluating Implementation of an Evidence-based Physical and Occupational Therapy (LSVT BIG®) for Parkinson’s Disease: Germany, France and Japan

C. Fox, L. Guse, L. Ramig (Tucson, AZ, USA)
Evaluating Multimodal Integration of Abnormalities in Adult Onset Idiopathic Focal Dystonia (AOIFD) via Multivariate Pattern Analysis (MVPA) and Ensemble Learning (EL)

S. Narasimham, D. Valeriani, S. O'Riordan, M. Hutchinson, K. Simonyan, R. Reilly (Dublin, Ireland)
Evaluating Perceptions of Deep Brain Stimulation in DBS-naïve Patients with Parkinson’s Disease – A Pilot Study

S. Das, S. Ramesh, M. Baldassari, M. Rasool, J. Ratliff, D. Kremens, T. Alexander, C. Matias, TW. Liang, C. Wu (Philadelphia, PA, USA)
Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases

A. Shim, V. Abler, N. Rashid (San Diego, CA, USA)
Evaluating the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease in USA: Interim-evidence from the PROviDE study

R. Pahwa, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Kansas City, KS, USA)
Evaluating the real-world impact of levodopa/carbidopa intestinal gel (LCIG) on motor symptoms using wearable sensors: Evidence from PROviDE study

R. Pahwa, R. Dorsey, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, N. Gupta, I. Pan, Y. Bao, D. Heldman (Kansas City, KS, USA)
Evaluating Volume Changes in the Substantia Nigra Pars Compacta (SNc) in Parkinson’s Disease (PD) in a Study-Specific Magnetic Resonance Imaging (MRI) Template

E. Biondetti, R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabregue, C. Ewenczyk, M. Hutchison, JC. Corvol, MJ. Vidailhet, S. Lehéricy (Paris, France)
Evaluation and Intervention of Aquatic Physiotherapy in People with Parkinson’s Disease: Repercussions on Balance

V. Israel, D. Iucksch, J. Siega, A. Silva, B. Yamaguchi, M. Ferreira (Curitiba, Brazil)
Evaluation of bedside screening tests to detect dysphagia in Parkinson’s disease

F. Brugger, J. Walch, M. Galovic, S. Hägele-Link, S. Stöckli, M. Müller-Baumberger, G. Kägi (St. Gallen, Switzerland)
Evaluation of Childhood Tremor Electrophysiogically Influences Diagnosis and Treatment and Outcome

B. Lavenstein, E. Akano, M. Hallett (Bethesda, MD, USA)
Evaluation of Clinical Peculiarities of Violations of Vertical Vision in Patients with Parkinson’s Disease

M. Salokhiddinov, D. Akramova (Tashkent, Uzbekistan)
Evaluation of Constipation in Patients with Parkinson’s Disease and its Correction

M. Salokhiddinov, D. Akramova (Tashkent, Uzbekistan)
Evaluation of corneal parameters in patients with idiopathic REM Sleep Behavior Disorder

S. You, KT. Kim, J. Jun, YW. Cho (Daegu, Republic of Korea)
Evaluation of Device-Assisted Treatment using a wearable accelerometry wrist sensor

A. Johansson, M. Lundgren, M. öthman, D. Nyholm (Stockholm, Sweden)
Evaluation of dose rate of photobiomodulation (light) therapy in patients with Parkinson’s Disease: Double blind placebo-controlled pilot trial. Is there a dose frequency per week that influences quality of life, mobility and cognition?

J. Bullock-Saxton, L. Laakso, A. Lehn, F. Read, K. Harm, A. Gosling, S. Hardy, P. Newcombe, A. Nolan, E. Tune (Brisbane, Australia)
Evaluation of gut microbiota in patients with Parkinson’s disease using a gas chromatography–mass spectrometry in Russia

I. Krasakov, I. Litvinenko (Saint-Petersburg, Russian Federation)
Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, F. Niccolini, G. Dervenoulas, R. Tyacke, J. Myers, R. Gunn, D. Nutt, E. Rabiner, S. Tabrizi, M. Politis (London, United Kingdom)
Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis (London, United Kingdom)
Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease

A. Prochiantz, G. Porras, A. Simonnet, E. Pioli, C. Friedel, E. Bézard, A. Bousseau (Paris, France)
Evaluation of nigral neuronal apoptosis during postnatal development and adulthood of mice strains with differential sensitivity to MPTP

Y. H, V. Dj, C. Sagar, R. Tr, P. Alladi (Bangalore, India)
Evaluation of Retinal Layers in Restless Legs Syndrome

N. Ongun, G. Ongun (Burdur, Turkey)
Evaluation of swallowing function by video-fluorography in patients with parkinsonism

S. Nogawa, Y. Chin, H. Kanke, R. Kawamura, T. Nakayama, K. Tokuoka, T. Furukawa (Tokyo, Japan)
Evaluation of the Zeez Sleep Pebble for Sleep Disturbance in Parkinson’s Disease

S. Milne, S. Cummins, C. Carroll (Plymouth, United Kingdom)
Evidence of altered Serotonergic Network in Parkinson’s disease by using a multi-modal MRI and PET imaging approach

SP. Caminiti, Z. Chappell, A. Carotenuto, G. Dervenoulas, T. Yousaf, G. Pagano, H. Wilson, M. Politis (London, United Kingdom)
Evidence of survival and integration of implanted autologous peripheral nerve graft in substantia nigra in a patient with Parkinson’s disease

DR. Ginjupally, G. Quintero, Z. Guduru, J. Gurwell, J. Slevin, A. Granholm, G. Gerhardt, C. van Horne (Denver, CO, USA)
Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease

S. Neo, A. Wong, HL. Ng, W. Li, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)
Evolution of ataxia in risk persons for spinocerebellar ataxia (SCA)

H. Jacobi, S. Tezenas Dumontcel, T. Klockgether, O. The-Risca-Investigators (Bonn, Germany)
Examining level of hemoglobin in patients with parkinson’s disease and the role of hemoglobin level in the disease course

SH. Shohimardonov, K. Daminova (Tashkent, Uzbekistan)
Examining supplementary motor area-primary motor cortex connectivity in tremor-dominant Parkinson’s disease using a novel transcranial magnetic stimulation protocol to inform clinical practice

BK. Rurak, J. Rodrigues, B. Power, P. Drummond, AM. Vallence (Murdoch, Australia)
Executive functions correlate with DaT-SPECT laterality in Parkinson’s disease

T. Alvarez-Avellon, E. Suarez-San Martin, C. Garcia-Fernandez, J. Alvarez-Carriles, R. Ribacoba, F. Cuetos, M. Menendez-Gonzalez (Oviedo, Spain)
Exercise and physical activity for people with Progressive Supranuclear Palsy

S. Slade, D. Finkelstein, J. Mcginley, M. Morris (Ivanhoe, Australia)
Exergame training in Early Onset Ataxia patients

R. Brandsma, I. Ganzevoort, M. Berg, ZT. Dominguez Vega, LD. Jelsma, MM. Schoemaker, NM. Maurits, CJC. Lamoth, DA. Sival (Groningen, Netherlands)
Exosomes from patients with Parkinson’s disease are pathological in mice

C. Han, N. Xiong, X. Guo, J. Huang, K. Ma, L. Liu, Y. Xia, S. Yin, L. Kou, F. Wan, J. Hu, G. Zhang, T. Wang (Wuhan, China)
Expanding the Phenotype of KCNA2 Mutation: Tics and Stereotypies

J. Legacy, M. Burns, A. Elkouzi, W. Deeb, I. Malaty (Gainesville, FL, USA)
Expenditures on pesticides and incidence of Parkinson’s disease in French farmers: a nationwide study

L. Perrin, J. Spinosi, L. Chaperon, S. Kab, F. Moisan, A. Elbaz (Villejuif Cedex, France)
Experimental model of developing of Parkinson’s disease

M. Tukhtamishev, F. Akhmedova (Tashkent, Uzbekistan)
Exploratory Analysis of Electrocortical Signal Complexity in Patients with Progressive Supranuclear Palsy and Corticobasal Degeneration

G. Mostile, L. Giuliano, R. Terranova, A. Luca, G. Donzuso, G. Portaro, C. Rascunà, V. Sofia, A. Nicoletti, M. Zappia (Catania, Italy)
Exploratory analysis of the relationship between pain and mood disturbances in Parkinson’s disease

C. Vila, A. Sparks, P. Imbriani, N. Caputi, L. Covington, T. Schirinzi, S. Natoli, A. Pisani, P. Ghosh (Washington, DC, USA)
Exploring anti-hypertensives as possible disease modifying agents in Parkinson’s disease using artificial intelligence and epidemiology

N. Visanji, S. Hensley Alford, A. Lacoste, P. Madan, I. Buleje, Y. Han, S. Spangler, L. Kalia, C. Marras (Toronto, ON, Canada)
Exploring the cognitive workload during a visual search task in Parkinson’s disease

M. Ranchet, J. Morgan, A. Akinwuntan, H. Devos (Kansas City, KS, USA)
Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)
Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)
Exploring the Lexicon of Fatigue in Parkinson Disease: A Qualitative Approach

S. Mantri, S. Albert, S. Kahl, M. Daeschler, E. Mamikonyan, C. Kopil, C. Marras, L. Chahine (Durham, NC, USA)
Exploring the relationship between motor and non-motor fluctuations in Parkinson’s disease: patient’s perspective, clinician’ s assessment and objective measures from a wearable device

A. Leake, A. de Angelis, M. Horne, D. Paviour, J. Coebergh, M. Edwards, F. Morgante, L. Ricciardi (London, United Kingdom)
Exposed-Only Analysis of Gene-Pesticide Interaction in Parkinson’s Disease (PD)

J. Kaye, L. Lima, C. Tanner, S. Finkbeiner, R. Swanson, S. Goldman (San Francisco, CA, USA)
Expression analysis of candidate genes in a cell model of affected and unaffected THAP1 mutation carriers and controls

H. Baumann, M. Trilck-Winkler, M. Grosse, A. Münchau, V. Kostic, C. Klein, F. Kaiser, P. Seibler, K. Lohmann (Belgrade, Serbia)
Expression profiles from CD14+ monocytes in PD patients with GBA mutations

G. Riboldi, E. Udine, E. Navarro, M. Parks, B. Henderson, K. Sharma, T. Sikder, M. Zhuang, J. Crary, S. Frucht, T. Raj (New York, NY, USA)
Extracellular α-synuclein enters dopaminergic neurons by modulating flotillin-1-assisted DAT endocytosis

T. Hasegawa, J. Kobayashi, N. Sugeno, S. Yoshida, T. Akiyama, Y. Miki, M. Fukuda, M. Ezura, A. Kikuchi, T. Baba, A. Takeda, K. Wakabayashi, H. Okano, M. Aoki (Sendai, Japan)
Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123I-FP-CIT study

A. Pilotto, F. Schianodicola, E. Premi, R. Grasso, R. Turrone, S. Gipponi, A. Scalvini, E. Cottini, B. Pagherà, V. Garibotto, MC. Rizzetti, L. Bonanni, B. Borroni, S. Morbelli, F. Nobili, UP. Guerra, D. Perani, A. Padovani (Brescia, Italy)